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Abstract 
Purpose. Adverse drug reactions (ADR) including medication allergies are not well-
described among large national cohorts. This study described the most common 
documented medication allergies and their reactions among a national cohort of 
Veterans Affairs (VA) inpatients.  
Methods. We evaluated inpatient admissions in any VA Medical Center from 1/1/2000 
to 12/31/2014. Each admission was linked with allergy history preceding or upon 
admission. Individual drugs were aggregated into drug class category including: 
penicillins, sulfonamides, angiotensin converting enzyme (ACE) inhibitors, opiates, 
HMG-CoA reductase inhibitors (“statins”) and non-steroidal anti-inflammatory inhibitors 
(NSAID). Results were reported in aggregate and over time. 
Results. Approximately ~10.8 million inpatient admissions occurred from 2000 – 2014. 
We found the most commonly reported allergy drug classes were penicillins (13%, 
n=1,410,080), opiates (9.1%, n=984,978), ACE inhibitors (5.7%, n=618,075) 
sulfonamides (5.1%, n=558,653), NSAIDs (5.1%, n=551,216) and statins (3.6%, 
n=391,983). Several allergy histories increased over time including opiates (6.2 to 
11.2%), ACE inhibitors (1.3 to 10.2%), statins (0.3 to 7.3%) and NSAIDs (3.9 to 6.0%). 
Rash was the most commonly documented reaction on reports for penicillins (25.5%, 
n=371,825), sulfonamides (25.6%, n=165,954), and NSAIDs (10.3%, n=65,741). The 
most common reaction for opiates was nausea/vomiting (17.9%, n=211,864), 
cough/coughing for ACE inhibitors (41.0%, n=270,537) and muscle pain/myalgia for 
statins  (34.1%, n=186,565).  
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Conclusions. We report that penicillins and opiates are the most commonly 
documented drug allergies among VA inpatients, but other drug classes such as ACE 
inhibitors, statins and NSAIDs are becoming increasingly common. Clinicians also 
commonly document non-allergic ADRs in the allergy section such as cough or myalgia.   
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Introduction 
Adverse drug reactions (ADR) including medication allergies are a common and 
burdensome reality in patients’ treatment. However ADRs are difficult to study in large 
databases because they are often not identified in health claims or other reports.1, 2 
Allergy databases may represent an important potential data source for studying ADRs. 
Thus, we undertook a study to describe the most common documented medication 
allergies and their reactions among inpatients receiving care in the Veterans Affairs 
(VA) health care system. We focused on the VA health care system for two reasons. 
First, the VA is the nation’s largest integrated health care delivery system, caring for 
approximately 9 million Veterans and operating 144 medical centers and 1200 
outpatient clinics throughout the US.3 Second, the VA’s comprehensive electronic 
health record includes detailed information on documented “allergies” to specific 
medications.  
Methods 
We evaluated inpatient admissions in any VA Medical Center from 1/1/2000 to 
12/31/2014. Admissions included acute care as well as short-stay observations, 
domiciliary stays, or long-term nursing care stays during the study period. Each unique 
admission was linked with allergy history preceding or upon admission. Allergy histories 
correspond to the general allergy section of the electronic medical record and could be 
documented from a variety of previous health encounters (e.g. previous admission, 
outpatient clinic or pharmacy visit). Individuals without any allergy records were 
assumed to have no known drug allergies. For comparison to previous studies, we 
identified individual drugs and combined them into their respective drug class 
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category.4,5 Natural and other synthesized penicillins were combined into one “penicillin-
class” category (e.g. penicillin, ampicillin, amoxicillin, methicillin, dicloxacillin, oxacillin, 
nafcillin, piperacillin, carbenicillin and ticarcillin). Sulfonamides included documented 
“sulfa” allergies not otherwise specified or specific sulfonamide antibiotic (trimethoprim, 
sulfacetamide, sulfadiazine, sulfamethoxazole, sulfasalazine and dapsone). Angiotensin 
converting enzyme (ACE) inhibitors included lisinopril, enalapril, ramipril, quinapril, 
perindopril, benazepril, fosinopril and captopril. Opiates included codeine, morphine, 
fentanyl, hydromorphone, oxycodone, methadone and meperidine. HMG-CoA 
reductase inhibitors (“statins”) included simvastatin, atorvastatin, rosuvastatin, 
pravastatin, fluvastatin and lovastatin. Non-steroidal anti-inflammatory inhibitors 
(NSAID) included aspirin, ibuprofen, naproxen, indomethacin, ketorolac, diclofenac, 
sulindac, etodolac, piroxicam and meloxicam. This study was approved by the 
Providence VA Institutional Review Board and Research and Development Committee. 
Results 
Overall we identified 2,948,543 patients with 10,858,398 admissions from 2000 – 
2014. These admissions were included from 127 VA Medical Centers across 48 states, 
Washington D.C. and Puerto Rico. Among admissions, 95.2% (n=10,339,233) were 
male, with a mean age of 63 (± 14 years). We found the most common allergies were 
penicillins (13%, n=1,410,080), opiates (9.1%, n=984,978), ACE inhibitors (5.7%, 
n=618,075) sulfonamides (5.1%, n=558,653), NSAIDs (5.1%, n=551,216) and statins 
(3.6%, n=391,983). The most common individual drugs included penicillin, codeine, 
lisinopril, simvastatin, morphine, aspirin and trimethoprim/sulfamethoxazole (Table 1).  
Penicillins and sulfonamides allergies increased ≤1% during the study period (Figure 1). 
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The other allergy histories that increased over time included opiates (6.2 to 11.2%), 
ACE inhibitors (1.3 to 10.2%), statins (0.3 to 7.3%) and NSAIDs (3.9 to 6.0%). 
Missing documentation about reactions was common ranging from 22.5 to 43.3% of 
reports by drug class (Table 1). Rash was the most commonly documented reaction on 
reports for penicillins (25.5%, n=371,825), sulfonamides (25.6%, n=165,954), and 
NSAIDs (10.3%, n=65,741). The most common reaction for opiates was 
nausea/vomiting (17.9%, n=211,864). Cough/coughing was the most common reaction 
for ACE inhibitor allergy reports (41.0%, n=270,537). Statin allergies most commonly 
stated a muscle pain/myalgia reaction on reports (34.1%, n=186,565). 
Discussion 
We report that penicillins and opiates are the most commonly documented drug 
allergies among inpatients in the VA system, but other drug classes such as ACE 
inhibitors, statins and NSAIDs are becoming increasingly common. Previous studies 
have found similar rates of penicillin allergies, and it is commonly reported that 10-15% 
of admitted patients are allergic to penicillins.6-9 A similarly designed study of health 
care plan members in the Southern California Kaiser Permanente system, which 
included both inpatients and outpatients found overall lower allergy prevalence rates 
(penicillin [7.9%], sulfonamide [4.3%], narcotic [3.7%], NSAIDs [2.1%], ACE inhibitors 
[1.3%]) than our study.5 However, they also found ACE inhibitors, NSAIDs and narcotics 
to be among the most commonly reported allergies. Only one other published study has 
investigated documented allergy trends over time.4 This single-center study which 
evaluated allergy prevalence from 1990-2013 reported similar prevalence findings for 
penicillins (12.8%), ACE inhibitors (2.0%), sulfonamides (7.4%), opiates (6.8%), and 
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NSAIDs (3.5%), as well as demonstrating a similar increase in ACE inhibitor, opiate, 
and statin allergies over time. Few studies have described the type of reactions reported 
by patients/providers. In a single-center study with retrospective chart review and 
patient interview which evaluated documented antimicrobial allergies and patient 
reported reactions, type I-IV hypersensitivity for penicillins and sulfonamides were 
classified for 69/198 [35%] and 28/88 [32%] of allergies respectively.12 A large national 
evaluation of outpatient medical records  demonstrated that the presence of an “allergic-
like event” (a combined definition of anaphylaxis, urticaria, angioedema and severe skin 
reactions) to penicillin does increase the likely occurrence of another reaction to 
cephalosporin or sulfonamide, but serious allergic hypersensitivities are relatively rare 
overall (<0.001%).13  
In our study, the large number of ACE inhibitor and statin “allergies” and their 
increase over time was unanticipated. ACE inhibitor and statin allergic hypersensitivities 
have not previously been described with comparable frequency to opiates and 
sulfonamide drugs.10 Documentation is subject to the historian judgment and patient 
recall, therefore the term “allergy” could also refer to other serious non-allergic ADRs 
which were deemed appropriate to document at the time. This is supported by our 
findings on the most commonly described reactions with each drug (Table 1).    
Clinicians may document non-allergic ADRs in the allergy domain to inform other 
providers to avoid these medications, such as ACE inhibitor-induced cough or muscle 
pain from statin therapy. These commonly reported ADRs (e.g. ACE inhibitor cough) 
raise the possibility that the “allergy” histories of VA patients (and possibly other 
electronic medical record systems) may contain substantial information on a variety of 
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historical adverse drug reactions not just allergic reactions. Review of allergy domains in 
electronic medical record systems may prove to be an untapped source for 
pharmacovigilance and post-marketing surveillance of medications. Future electronic 
health record (EHR) innovations could explicitly divide these sections into “allergy”, 
“intolerance”, and “food” to reduce this technical inaccuracy. A system which allows for 
greater specificity in documenting drug and food reactions could improve patient safety 
as clinicians will be able to make better informed decisions for patient management in 
the presence of such reaction histories.  A significant limitation to this approach may be 
the accuracy of the documented allergy. Inaccuracy in documentation can be two-fold, 
1) the history could be inaccurately recorded or 2) the history even when accurately 
taken from the patient may not actually be related to any real hypersensitivity. Patients 
with documented penicillin allergies often do not have physiologic reactions, but among 
other documented “allergies” the overall likelihood of actual ADRs after rechallenge is 
not well-described.14 One study compared documented allergy records vs. actual 
patient interview in an emergency department setting and found significant 
discordance.15  
In our study, the reactions reported generally reflect the ADR profile of that agent 
(i.e. cough, angioedema, hyperkalemia for ACE inhibitors; Table 1) and even if the 
allergy documentation is inaccurate, these “allergies” could still be useful as they 
influence treatment decisions regardless of the accuracy.8 Therefore, we highlight the 
opportunity to investigate documented “allergies” with regards to general ADR trends 
and how they impact drug utilization and health outcomes.  
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Document Allergies Over Time, 2000-2014 
 Penicillins Opiates ACE inhibitors Sulfonamides NSAID Statins 
Admissions 
with any 
allergy 
1,410,080 (13.0) 984,978 (9.1) 618,075 (5.7) 558,653 (5.1) 551,216 (5.1) 391,983 (3.6) 
By druga 
(% of 
class) 
Penicillin 
1,289,229 (91.4) 
Codeine 
526,825 (53.5) 
Lisinopril 
474,567 (76.8) 
NOS 
414,214 (74.1) 
Aspirin  
251,907 (45.7) 
Simvastatin 
307,316 (78.4) 
Amoxicillin 
96,348 (6.8) 
Morphine 
268,332 (27.2) 
NOS 
62,380 (10.1) 
TMP/SMX 
188,792 (33.8) 
Ibuprofen 
171,730 (31.2) 
Atorvastatin 
64,025 (16.3) 
Ampicillin 
37,211 (2.6) 
Oxycodone 
121,870 (12.4) 
Fosinopril 
61,778 (10.0) 
Sulfacetamide 
17,165 (3.1) 
Naproxen  
69,599 (12.6) 
Pravastatin 
48,659 (12.4) 
Piperacillin 
17,939 (1.3) 
Meperidine 
95,179 (9.7) 
Enalapril 
19,694 (3.2) 
Sulfasalazine 
7,924 (1.4) 
Ketorolac  
34,169 (6.2) 
Rosuvastatin 
37,865 (9.7) 
Dicloxacillin 
7,275 (0.5) 
Hydrocodone 
92,661 (9.4) 
Benazepril 
16,575 (2.7) 
Sulfadiazine 
4,956 (0.9) 
Indomethacin 
26,815 (4.9) 
Fluvastatin 
29,045 (7.4) 
Total 
allergiesb 
1,458,269 1,181,299 660,563 647,948 638,643 547,168 
By 
reactionc 
(% of 
allergies) 
Rash 
371,825 (25.5) 
Nausea/ 
vomiting 
211,864 (17.9) 
Cough/ 
coughing  
270,537 (41.0) 
Rash  
165,954 (25.6) 
Rash  
65,741 (10.3) 
Muscle pain/ 
myalgia 
186,565 (34.1) 
Hives/urticaria 
201,828 (13.8) 
Rash  
130,176 (11.0) 
“Other”  
43,946 (6.7) 
Hives/urticaria 
67,806 (10.5) 
Nausea/vomiting 
64,208 (10.1) 
“Other”  
 50,609 (9.2) 
“Other”  
 62,036 (4.3) 
Hives/urticaria 
75,202 (6.4)  
Angioedema 
42,312 (6.4) 
“Other”  
 33,515 (5.2) 
 “Other”  
 60,919 (9.5) 
Weakness 
22,316 (4.1) 
Swelling/ edema  
85,687 (5.9) 
“Other”,  
 58,143 (4.9) 
Hyperkalemia 
28,968 (4.4) 
Nausea/vomiting 
32,652 (5.0) 
Hives/urticaria 
41,897 (6.6) 
Rash  
18,742 (3.4) 
Anaphylaxis 
45,573 (3.1) 
Pruritis  
12,695 (1.1) 
Rash  
21,445 (3.2) 
Anaphylaxis  
8,310 (1.3) 
GI reaction 
15,471 (2.4) 
Diarrhea 
11,666 (2.1) 
Missing 
reaction 
632,073 (43.3) 415,459 (35.2) 148,629 (22.5) 273,798 (42.3) 247,827 (38.8) 133,793 (24.5) 
Description. Total admissions (n=10,858,398). The most common allergy classes, individual drugs and the most common 
reactions reported. ACE – angiotensin converting enzyme, NSAID – non-steroidal anti-inflammatory drugs, N/V – 
Nausea/Vomiting, GI - gastrointestinal. NOS – Not otherwise specified. TMP/SMX – Trimethoprim/Sulfamethoxazole.  
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a- An individual admission could have multiple allergies in the same class listed so these values exceed the “any allergy” 
count (e.g. patient had both penicillin and amoxicillin listed).  
b- “Total allergies” refers to unique individual allergy records per admission (vs. any allergy).  
c- Each allergy could have more than one recorded reaction so reaction counts exceed total allergies. Allergy histories 
stated “other reaction” for many entries. 
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Figure 1. Veteran Health Administration documented “allergies” among inpatient 
admissions from 2000 - 2014. ACEi – angiotensin converting enzyme inhibitors, 
NSAIDs – non-steroidal anti-inflammatory drugs. 
 
 
